National multidrug-resistant bacteria (MDRB) surveillance in France through the RAISIN network: A 9 year experience

Journal of Antimicrobial Chemotherapy

Volumn 68, Issue 4, 2013, Pages 954-959

  Carbonne, Anne ^a   Arnaud, Isabelle ^a   Maugat, Sylvie ^b   Marty, Nicole ^c   Dumartin, Catherine ^d   Bertrand, Xavier ^e   Bajolet, Odile ^f   Savey, Anne ^g   Fosse, Thierry ^h   Eveillard, Mathieu ⁱ   Sénéchal, Hélène ^a   Coignard, Bruno ^b   Astagneau, Pascal ^j   Jarlier, Vincent ^k,l   Caillat Vallet, Emmanuelle ^m   Garreau, Nadine ^m   Hoff, Olivier ^m   Simon, Loïc ^m   Marian, Sandrine ^m   Parneix, Pierre ^m   Reyreaud, Emmanuelle ^m   Sousa, Elisabeth ^m   Trystram, David ^m   Lebascle, Karin ^m   more..

^a CCLIN Paris Nord   (France)

^b InVS   (France)

^c TOULOUSE UNIVERSITY HOSPITAL   (France)

^d CCLIN Sud Ouest   (France)

^e UNIVERSITY HOSPITAL OF BESANÇON   (France)

^f REIMS UNIVERSITY HOSPITAL   (France)

^g Hopital Henry Gabrielle   (France)

^h UNIVERSITY HOSPITAL OF NICE   (France)

ⁱ ANGERS UNIVERSITY HOSPITAL   (France)

^j Hotel Dieu CHU Rennes   (France)

^k SORBONNE UNIVERSITÉ   (France)

^l PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^m NONE

more..

Author keywords

ESBLE; Healthcare setting; MRSA; Prevention; Programme

Indexed keywords

ARTICLE; DISEASE SURVEILLANCE; ENTEROBACTER AEROGENES; ESCHERICHIA COLI; EXTENDED SPECTRUM BETA LACTAMASE PRODUCING ENTEROBACTERIACEAE; FRANCE; HEALTH CARE FACILITY; INCIDENCE; INTENSIVE CARE UNIT; KLEBSIELLA PNEUMONIAE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NONHUMAN; PROSPECTIVE STUDY;

ANTI-BACTERIAL AGENTS; BETA-LACTAMASES; CROSS INFECTION; DRUG RESISTANCE, MULTIPLE, BACTERIAL; ENTEROBACTERIACEAE; ENTEROBACTERIACEAE INFECTIONS; FRANCE; HOSPITALS; HUMANS; INCIDENCE; INFECTION CONTROL; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCAL INFECTIONS;

EID: 84875256513     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dks464     Document Type: Article

References (22)

1. Resch A, Wilke M, Fink C. The cost of resistance: incremental cost of methicillin-resistant Staphylococcus aureus (MRSA) in German hospitals. Eur J Health Econ 2009; 10: 287-97.
2. Pitout JDD, Laupland KB. Extended-spectrum β-lactamase-producing Enterobacteriaceae: an emerging public-health concern. Lancet Infect Dis 2008; 8: 159-66.
3. Voss A, Milatovic D, Wallrauch SC et al. Methicillin-resistant Staphylococcus aureus in Europe. Eur J Clin Microbiol Infect Dis 1994; 13: 50-5.
4. Johnson AP. Methicillin-resistant Staphylococcus aureus: the European landscape. J Antimicrob Chemother 2011; 66 Suppl 4: iv43-8.
5. Carlet J, Astagneau P, Brun-Buisson C et al. French national program for prevention of healthcare-associated infections and antimicrobial resistance, 1992-2008: positive trends, but perseverance needed. Infect Control Hosp Epidemiol 2009; 30: 737-45.
6. Desenclos J-C. RAISIN-a national programme for early warning, investigation and surveillance of healthcare-associated infection in France. Euro Surveill 2009; 14: piix00BC;19408.
7. Soussy CJ, Carret G, Cavallo JD et al. [Antibiogram Committee of the French Microbiology Society. Report 2000-2001]. Pathol Biol (Paris) 2000; 48: 832-71.
8. Réseau d'Alerte d'Investigation et de Surveillance des Infections Nosocomiales (RAISIN). Surveillance des bactéries multirésistantes dans les établissements de santé en France - Résultats 2003. http://opac.invs.sante. fr/doc_num.php?explnum_id=4592(3 September 2012, date last accessed).
9. Albertini MT, Benoit C, Berardi L et al. Surveillance of methicillinresistant Staphylococcus aureus (MRSA) and Enterobacteriaceae producing extended-spectrum b-lactamase (ESBLE) in Northern France: a five-year multicentre incidence study. J Hosp Infect 2002; 52: 107-13.
10. Jarlier V, Trystram D, Brun-Buisson C et al. Curbing methicillinresistant Staphylococcus aureus in 38 French hospitals through a 15-year institutional control program. Arch Intern Med 2010; 170: 552-9.
11. Siegel JD, Rhinehart E, Jackson M et al. 2007 Guideline for isolation precautions: preventing transmission of infectious agents in health care settings. Am J Infect Control 2007; 35: S65-164.
12. European Centre for Disease Prevention and Control. Antimicrobial resistance surveillance in Europe 2010. Annual report of the European Antimicrobial Resistance Surveillance Network (EARS-Net). http://www. ecdc.europa.eu/en/publications/Publications/Forms/ECDC_DispForm.aspx? ID=774 (3 September 2012, date last accessed).
13. Johnson AP, Davies J, Guy R et al. Mandatory surveillance of methicillin-resistant Staphylococcus aureus (MRSA) bacteraemia in England: the first 10 years. J Antimicrob Chemother 2012; 67: 802-9.
14. Haut Conseil de la Santé Publique. Recommandations relatives aux mesures a' mettre en oeuvre pour prévenir l'émergence des entérobactéries BLSE et lutter contre leur dissémination - Propositions rédigées dans l'optique de définir un programme national de prévention, 2010. http://www.hcsp.fr/explore.cgi/hcspr20100202_enterobactBLSE. pdf (3 September 2012, date last accessed).
15. Lietzau S, Raum E, von Baum H et al. Household contacts were key factor for children's colonization with resistant Escherichia coli in community setting. J Clin Epidemiol 2007; 60: 1149-55.
16. Madec J-Y, Lazizzera C, Châtre P et al. Prevalence of fecal carriage of acquired expanded-spectrum cephalosporin resistance in Enterobacteriaceae strains from cattle in France. J Clin Microbiol 2008; 46: 1566-7.
17. Tängdén T, Cars O, Melhus A et al. Foreign travel is a major risk factor for colonization with Escherichia coli producing CTX-M-type extendedspectrum β-lactamases: a prospective study with Swedish volunteers. Antimicrob Agents Chemother 2010; 54: 3564-8.
18. Bertrand X, Hocquet D, Boisson K et al. Molecular epidemiology of Enterobacteriaceae producing extended-spectrum β-lactamase in a French university-affiliated hospital. Int J Antimicrob Agents 2003; 22: 128-33.
19. Rodri{dotless}́guez-Ban{ogonek}o J, Navarro MD, Romero L et al. Bacteremia due to extended-spectrum b-lactamase-producing Escherichia coli in the CTX-M era: a new clinical challenge. Clin Infect Dis 2006; 43: 1407-14.
20. Drieux L, Brossier F, Duquesnoy O et al. Increase in hospital-acquired bloodstream infections caused by extended spectrum b-lactamaseproducing Escherichia coli in a large French teaching hospital. Eur J Clin Microbiol Infect Dis 2009; 28: 491-8.
21. Bauernfeind A. Perspectives of b-lactamases inhibitors in therapy of infections caused by Escherichia coli or Klebsiella with plasmidic resistance to third generation cephalosporins. Infection 1990; 18: 48-52.
22. Coque TM, Novais A, Carattoli A et al. Dissemination of clonally related Escherichia coli strains expressing extended-spectrum b-lactamase CTX-M-15. Emerging Infect Dis 2008; 14: 195-200.